{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:04:00Z","timestamp":1784541840010,"version":"3.55.0"},"reference-count":46,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15704","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:34:11Z","timestamp":1781602451000},"page":"1-13","source":"Crossref","is-referenced-by-count":0,"title":["Double vs. single autologous stem cell transplantation in patients with multiple myeloma and high\u2011risk factors: A systematic review and meta\u2011analysis"],"prefix":"10.3892","volume":"32","author":[{"given":"Sibei","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qionglin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People's Hospital of Shaoguan, Shaoguan Hospital of Southern Medical University, Shaoguan, Guangdong 512000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"key20260720122059_b1-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"key20260720122059_b2-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: Guidelines from the American society for blood and marrow transplantation","volume":"2","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20260720122059_b3-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","article-title":"European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Haematologica"},{"key":"key20260720122059_b4-ol-32-2-15704","first-page":"341","article-title":"The guidelines for the diagnosis and management of multiple myeloma in China (2020 revision)","volume":"59","author":"Chinese Hematology","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"key20260720122059_b5-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"key20260720122059_b6-ol-32-2-15704","first-page":"CD004626","article-title":"First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies","volume":"10","author":"Naumann-Winter","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20260720122059_b7-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"key20260720122059_b8-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"key":"key20260720122059_b9-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group MyelomeAutogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20260720122059_b10-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: Role of autologous transplantation","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"key20260720122059_b11-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"key20260720122059_b12-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20260720122059_b13-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3324\/haematol.11168","article-title":"Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Long-term follow-up of the Dutch Cooperative Group HOVON 24 trial","volume":"92","author":"Sonneveld","year":"2007","journal-title":"Haematologica"},{"key":"key20260720122059_b14-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: Long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai","year":"2016","journal-title":"Br J Haematol"},{"key":"key20260720122059_b15-ol-32-2-15704","first-page":"S401","article-title":"Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: An analysis of phase 3 EMN02\/H095 study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"key":"key20260720122059_b16-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1182\/blood-2018-99-112899","article-title":"Double vs. single autologous stem cell transplantation for newly diagnosed multiple myeloma: Long-term follow-up (10-years) analysis of randomized phase 3 studies","volume":"132","author":"Cavo","year":"2018","journal-title":"Blood"},{"key":"key20260720122059_b17-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20260720122059_b18-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jnci\/djp128","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"key20260720122059_b19-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key20260720122059_b20-ol-32-2-15704","article-title":"Cochrane handbook for systematic reviews of interventions version 5.0.0","volume-title":"Cochrane Collaboration","author":"Higgins","year":"2008"},{"key":"key20260720122059_b21-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key20260720122059_b22-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"key20260720122059_b23-ol-32-2-15704","article-title":"Netmeta: Network metaanalysis using frequentist methods","author":"R\u00fccker","year":"2016","journal-title":"Version 0.8\u20130"},{"key":"key20260720122059_b24-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"key20260720122059_b25-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"key20260720122059_b26-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/sim.2971","article-title":"Arcsine test for publication bias in meta-analyses with binary outcomes","volume":"27","author":"R\u00fccker","year":"2008","journal-title":"Stat Med"},{"key":"key20260720122059_b27-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/sim.6342","article-title":"Statistical methods for dealing with publication bias in meta-analysis","volume":"34","author":"Jin","year":"2015","journal-title":"Stat Med"},{"key":"key20260720122059_b28-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"key20260720122059_b29-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ejh.13690","article-title":"Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma","volume":"107","author":"Straka","year":"2021","journal-title":"Eur J Haematol"},{"key":"key20260720122059_b30-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood.V122.21.767.767","article-title":"Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: An integrated analysis of patient-level data from phase European III studies","volume":"122","author":"Cavo","year":"2013","journal-title":"Blood"},{"key":"key20260720122059_b31-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood-2018-99-112899","article-title":"Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: Long-term follow-up (10-years) analysis of randomized phase 3 studies","volume":"132","author":"Cavo","year":"2018","journal-title":"Blood"},{"key":"key20260720122059_b32-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20260720122059_b33-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/diagnostics14101030","article-title":"The efficacy and safety of tandem transplant versus single stem cell transplant for multiple myeloma patients: A systematic review and meta-analysis","volume":"14","author":"Chen","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"key20260720122059_b34-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"e00235","DOI":"10.1097\/BS9.0000000000000235","article-title":"Comparison of tandem and single autologous stem cell transplantation in multiple myeloma: A retrospective propensity score-matching study","volume":"7","author":"Wu","year":"2025","journal-title":"Blood Sci"},{"key":"key20260720122059_b35-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"2343164","DOI":"10.1080\/16078454.2024.2343164","article-title":"Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: A systematic review and meta-analysis","volume":"29","author":"Li","year":"2024","journal-title":"Hematology"},{"key":"key20260720122059_b36-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"e70573","DOI":"10.1002\/cam4.70573","article-title":"Tandem versus single autologous stem cell transplantation for high-risk multiple myeloma in the era of novel agents: A real-world study of China","volume":"14","author":"Dou","year":"2025","journal-title":"Cancer Med"},{"key":"key20260720122059_b37-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41409-024-02490-1","article-title":"Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"60","author":"Grieb","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"key20260720122059_b38-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jtct.2024.06.030","article-title":"Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients in the maintenance era: real-world results from the Canadian myeloma research group database","volume":"30","author":"Venner","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"key20260720122059_b39-ol-32-2-15704","first-page":"e18334","article-title":"The role of allogeneic stem cell transplantation in multiple myeloma: A systematic review of the literature","volume":"13","author":"Khorochkov","year":"2021","journal-title":"Cureus"},{"key":"key20260720122059_b40-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"1402106","DOI":"10.3389\/fonc.2024.1402106","article-title":"Allogeneic stem cell transplantation in multiple myeloma: Is there still a place?","volume":"14","author":"Liberatore","year":"2024","journal-title":"Front Oncol"},{"key":"key20260720122059_b41-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000542704","article-title":"Historical perspective of allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"148","author":"Aslam","year":"2025","journal-title":"Acta Haematol"},{"key":"key20260720122059_b42-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"2269509","DOI":"10.1080\/16078454.2023.2269509","article-title":"Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: A systematic review and meta-analysis","volume":"28","author":"Wei","year":"2023","journal-title":"Hematology"},{"key":"key20260720122059_b43-ol-32-2-15704","first-page":"1469","article-title":"Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: A prospective, phase II study","volume":"109","author":"Kr\u00f6ger","year":"2024","journal-title":"Haematologica"},{"key":"key20260720122059_b44-ol-32-2-15704","first-page":"289","article-title":"Historical perspective of high-dose therapy followed by autologous stem cell transplantation in multiple myeloma","volume":"148","author":"Cohen","year":"2025","journal-title":"Acta Haematol"},{"key":"key20260720122059_b45-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12885-023-10907-1","article-title":"Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: A systematic review and meta-analysis","volume":"23","author":"Lin","year":"2023","journal-title":"BMC Cancer"},{"key":"key20260720122059_b46-ol-32-2-15704","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41408-023-00905-8","article-title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: A report from the Canadian Myeloma Research Group database","volume":"13","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Blood Cancer J"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:21:04Z","timestamp":1784539264000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15704","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}